AI assistant
Sending…
Phathom Pharmaceuticals, Inc. — Director's Dealing 2019
Oct 25, 2019
32407_dirs_2019-10-24_c0478998-d4ac-4b05-98c9-dc82af447814.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Phathom Pharmaceuticals, Inc. (PHAT)
CIK: 0001783183
Period of Report: 2019-10-24
Reporting Person: TAKEDA PHARMACEUTICAL CO LTD (10% Owner)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 1084000 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Warrant | $ | 2029-05-07 | Common Stock (7588000) | Direct |
Footnotes
F1: The exercise price of the warrant is $0.00004613 per share of Common Stock.
More from Phathom Pharmaceuticals, Inc.
Regulatory Filings
2026
May 21
Interim / Quarterly Report
2026
Apr 30
Regulatory Filings
2026
Apr 30
Annual Report
2026
Apr 7
Proxy Solicitation & Information Statement
2026
Apr 7
Regulatory Filings
2026
Mar 27
Director's Dealing
2026
Mar 3
Annual Report
2026
Feb 26
Regulatory Filings
2026
Feb 26
Director's Dealing
2026
Feb 12